SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
about
Pancreatic β Cell Mass DeathSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsHypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in miceThe Role of INDY in Metabolic RegulationEfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Mitochondrial GTP insensitivity contributes to hypoglycemia in hyperinsulinemia hyperammonemia by inhibiting glucagon release.Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolismDissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice.SGLT-2 inhibition and glucagon: Cause for alarm?Structural selectivity of human SGLT inhibitors.The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 DiabetesTargeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.Saturated and unsaturated fat induce hepatic insulin resistance independently of TLR-4 signaling and ceramide synthesis in vivoSubstantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled StudyCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialTofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.A Renal Olfactory Receptor Aids in Kidney Glucose Handling.Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetesNonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?Empagliflozin for the treatment of Type 2 diabetes.Pharmacological treatment and therapeutic perspectives of metabolic syndrome.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.
P2860
Q26752571-447070AC-5A71-4466-BF82-17AE365E11F4Q28072765-EFAEA4CB-80C2-4A10-A800-1EC333E4AF48Q28732080-2D062CB6-B679-4747-AB67-0B4E5E4D5853Q34060577-B9517369-B86B-4705-B4DD-E010B2A10F29Q34413057-72F77E82-A6A9-4D30-BDE2-B506D757AA86Q34543009-C0412467-25F9-402C-9F54-F2F3B1B61119Q34545472-EAB981C3-DAAE-4513-A210-D1FDE79A5809Q35184821-DD8CF408-FB0D-405C-87AF-B53B1229A10FQ35192198-84BF756D-5A8E-4302-92E2-EF5EEBC66128Q35194026-90EE86E6-F305-455D-BD64-2329DD98EA08Q35214420-C09A87B8-C390-4F4D-80CF-93EF77A1D394Q35378742-962388B2-6BDF-4856-B0CF-7F1364761F6FQ35709954-35FAE6BD-C015-4398-873E-C095E9F74AAAQ35812506-E070E84B-801B-4547-8C1C-B43058E0B256Q35895528-990ABB92-EF32-4F8B-928F-F90BFC04B042Q35903101-919CCD7C-E9BB-4ACB-ACDE-F8E280B19E8CQ36175431-DAA12092-49B9-4A3A-B3ED-A7B9B9615284Q36372598-5694E565-2F58-4E7E-8EA7-3C5E7C6F1509Q36429733-06C001E8-AA56-4FDE-837B-5EA508E2A98DQ36745809-A160824C-0ABE-4280-BE64-5D647CD8BFC3Q37068691-04F890C4-E0D5-43E9-B62B-2F7E718EB228Q37080615-B9DF5A57-EF13-4A77-807B-8A653AB789C7Q37106527-FD796DEF-0BD1-4FED-88FE-6353AC42ABE8Q37219076-452D707A-127F-4C1D-8EC5-6B54492FADB9Q37339712-8999C6DC-B41E-499B-8E30-23FA32017B13Q37524302-97B3FF0C-C066-429F-B98C-937FAE1DF950Q37532069-A35B4904-942A-40AB-9E72-E387A0811B02Q37586729-A77534EB-F9AC-4D3E-AFDE-019E43A544B0Q37624982-78EE0602-4A9C-4005-A910-E8C5AB37A351Q37981884-6380CFB1-D975-4497-9CF8-05AE04A960C1Q38036770-F414E0CE-5C54-4A56-B84C-B4228C7B4111Q38075117-2DAE9C5A-9D77-48C8-A3E4-832D6723B976Q38085691-B0C607AA-2561-4435-84CB-A9675EEE36E3Q38104746-D9C0CCCC-9A63-4DDF-86FD-B7AF35BC6244Q38203327-AA6D82F7-FCD8-4B45-AD1E-C75243D308EBQ38262435-2719BA04-CDE4-494A-902F-12495B4E4E7BQ38330456-6308B6A0-0A10-4DDA-A785-150A10DA525AQ38468017-302CEBA0-C32F-4DC5-9721-9C8869AE2C4BQ38537119-F46BCF6B-35B5-447F-8B2E-2212E4C80F7FQ38597063-E80CF85A-7BFC-464C-AB6F-6D3A159BF4C8
P2860
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@en
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@nl
type
label
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@en
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@nl
prefLabel
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@en
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@nl
P2093
P2860
P356
P1433
P1476
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function
@en
P2093
Andreas L Birkenfeld
David W Frederick
Francois R Jornayvaz
Gilbert W Moeckel
Hui-Young Lee
Jean M Whaley
Michael J Jurczak
Rebecca L Pongratz
Richard G Kibbey
Varman T Samuel
P2860
P304
P356
10.2337/DB10-1328
P407
P577
2011-03-01T00:00:00Z